Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cholangiocarcinoma
- Cholangiocarcinoma Recurrent
- Mesothelioma
- Mesothelioma Peritoneum
- Mesothelioma Malignant
- Mesothelioma; Pleura
- Mesotheliomas Pleural
- Non -Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Ovarian Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03907852
- Collaborators
- Not Provided
- Investigators
- Study Chair: Clinical TCR2 Therapeutics
Get Well Soon